Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Curevac N.V. (NQ: CVAC )

2.875 -0.115 (-3.85%)
Streaming Delayed Price Updated: 12:08 PM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 105,371
Open 3.000
Bid (Size) 2.870 (8)
Ask (Size) 2.880 (4)
Prev. Close 2.990
Today's Range 2.865 - 3.000
52wk Range 2.215 - 12.36
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
Via Benzinga
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property

Performance

YTD
-31.38%
-31.38%
1 Month
-6.35%
-6.35%
3 Month
-19.01%
-19.01%
6 Month
-47.82%
-47.82%
1 Year
-65.98%
-65.98%

More News

Read More
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Via ACCESSWIRE
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Via ACCESSWIRE
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
Via ACCESSWIRE
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Via ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
Via ACCESSWIRE
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Via ACCESSWIRE
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert
Via Benzinga
CureVac, GS Partner Release Data On Influenza Vaccine Study
Via Benzinga
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Via ACCESSWIRE
Why Biopharmaceutical Player CureVac Shares Are Rising Today
Via Benzinga
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Via ACCESSWIRE
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
Via ACCESSWIRE
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
Earnings Scheduled For November 14, 2023
Via Benzinga
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
Via ACCESSWIRE
Why CureVac Stock Plunged Today
Via The Motley Fool
Topics Lawsuit
Exposures Financial Legal
3 Stocks to Buy For the COVID Resurgence
Via MarketBeat
Exposures COVID-19 Product Safety
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
Via ACCESSWIRE
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.